Biocon Ltd 2015 AR2
The report highlights Biocon's performance and initiatives for the fiscal year 2014-15. Biocon achieved a consolidated revenue of INR 31,429 million, representing a 7% year-on-year growth, with net profit increasing by 20% to INR 4,974 million. The company successfully commissioned its greenfield insulins manufacturing facility in Malaysia, the largest integrated facility in Asia. Biocon's CSR arm, Biocon Foundation, was recognized as a 'Public Health Champion' by WHO India for its sustainable public health solutions. Additionally, the company continued its commitment to environmental sustainability, reducing carbon dioxide emissions by 2,700 tonnes through the procurement of green power.
Company: Biocon Ltd
Sector: Manufacturing
Country: India
Year: 2015
Type: AR2
Pages: 216
Back to company
Biocon Ltd
Annual Report
The report highlights Biocon's performance and initiatives for the fiscal year 2014-15. Biocon achieved a consolidated revenue of INR 31,429 million, representing a 7% year-on-year growth, with net profit increasing by 20% to INR 4,974 million. The company successfully commissioned its greenfield insulins manufacturing facility in Malaysia, the largest integrated facility in Asia. Biocon's CSR arm, Biocon Foundation, was recognized as a 'Public Health Champion' by WHO India for its sustainable public health solutions. Additionally, the company continued its commitment to environmental sustainability, reducing carbon dioxide emissions by 2,700 tonnes through the procurement of green power.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Apr 1, 2014 - Mar 31, 2015
Fiscal Year
2015
Published
Jun 18, 2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees